Literature DB >> 2961806

Structural characterization of the human B lymphocyte-restricted differentiation antigen CD22. Comparison with CD21 (complement receptor type 2/Epstein-Barr virus receptor).

D R Boué1, T W Lebien.   

Abstract

CD22 and CD21 are glycoproteins primarily expressed on normal and neoplastic human B cells. The surface expression of these two molecules parallel each other during normal B cell differentiation, and the reported relative mobilities for CD22 and CD21 are 130/140 kDa and 140 kDa, respectively. Herein we present a detailed analysis of the biosynthesis and structure of CD22 and also compare it directly to CD21. Electrophoresis under reducing and nonreducing conditions suggested that CD22 and CD21 may have similarities in intra-chain disulfide bond formation. Biosynthesis and processing of CD22 and CD21 were very similar with respect to kinetics and post-translational modification, and both could be phosphorylated. However, endoglycosidase digestion (using N-glycanase and endoglycosidase H) and peptide mapping (using V8 protease and N-chlorosuccinimide) strongly suggested that CD22 and CD21 are distinct gene products.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2961806

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Differential expression of CD22 (Lyb8) on murine B cells.

Authors:  L D Erickson; L T Tygrett; S K Bhatia; K H Grabstein; T J Waldschmidt
Journal:  Int Immunol       Date:  1996-07       Impact factor: 4.823

2.  CD22 associates with the human surface IgM-B-cell antigen receptor complex.

Authors:  C Leprince; K E Draves; R L Geahlen; J A Ledbetter; E A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

3.  Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand.

Authors:  P Engel; N Wagner; A S Miller; T F Tedder
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

Review 4.  The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.

Authors:  Benjamin A H Smith; Carolyn R Bertozzi
Journal:  Nat Rev Drug Discov       Date:  2021-01-18       Impact factor: 84.694

5.  Unusual patterns of immunoglobulin gene rearrangement and expression during human B cell ontogeny: human B cells can simultaneously express cell surface kappa and lambda light chains.

Authors:  M E Pauza; J A Rehmann; T W LeBien
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

6.  A complex of glycoproteins is associated with VpreB/lambda 5 surrogate light chain on the surface of mu heavy chain-negative early precursor B cell lines.

Authors:  H Karasuyama; A Rolink; F Melchers
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

7.  cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions.

Authors:  G L Wilson; C H Fox; A S Fauci; J H Kehrl
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.